SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) provided a clinically meaningful overall survival benefit in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.